Skip to main content
Top
Published in:

03-01-2024 | Steatotic Liver Disease | REVIEW

Functional Food Chemical Ingredient Strategies for Non-alcoholic Fatty Liver Disease (NAFLD) and Hepatic Fibrosis: Chemical Properties, Health Benefits, Action, and Application

Authors: Chong Yu, Xiaohe Guo, Xiaohang Cui, Guangyue Su, Haifeng Wang

Published in: Current Nutrition Reports | Issue 1/2024

Login to get access

Abstract

Purpose of Review

The liver is an important digestive gland in the body. Lifestyle and dietary habits are increasingly damaging our liver, leading to various diseases and health problems. Non-alcoholic fatty liver disease (NAFLD) has become one of the most serious liver disease problems in the world. Diet is one of the important factors in maintaining liver health. Functional foods and their components have been identified as novel sources of potential preventive agents in the prevention and treatment of liver disease in daily life. However, the effects of functional components derived from small molecules in food on different types of liver diseases have not been systematically summarized.

Recent Findings

The components and related mechanisms in functional foods play a significant role in the development and progression of NAFLD and liver fibrosis. A variety of structural components are found to treat and prevent NAFLD and liver fibrosis through different mechanisms, including flavonoids, alkaloids, polyphenols, polysaccharides, unsaturated fatty acids, and peptides. On the other hand, the relevant mechanisms include oxidative stress, inflammation, and immune regulation, and a large number of literature studies have confirmed a close relationship between the mechanisms.

Summary

The purpose of this article is to examine the current literature related to functional foods and functional components used for the treatment and protection against NAFLD and hepatic fibrosis, focusing on chemical properties, health benefits, mechanisms of action, and application in vitro and in vivo. The roles of different components in the biological processes of NAFLD and liver fibrosis were also discussed.
Literature
1.
go back to reference Emir M, Dimitri PM, Christos M. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119: 154770.CrossRef Emir M, Dimitri PM, Christos M. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism. 2021;119: 154770.CrossRef
2.
go back to reference Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023;21(2):388–97.PubMedCrossRef Hsieh YC, Joo SK, Koo BK, Lin HC, Lee DH, Chang MS, et al. Myosteatosis, but not sarcopenia, predisposes NAFLD subjects to early steatohepatitis and fibrosis progression. Clin Gastroenterol Hepatol. 2023;21(2):388–97.PubMedCrossRef
3.
go back to reference Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017;15(1):11–20.PubMedCrossRef Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017;15(1):11–20.PubMedCrossRef
4.
go back to reference Anstee, Quentin M, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44. Anstee, Quentin M, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.
5.
go back to reference Yang Q, Zhang L, Li Q, Gu M, Qu Q, Yang X, et al. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. BMC Microbiol. 2022;22(1):105.PubMedPubMedCentralCrossRef Yang Q, Zhang L, Li Q, Gu M, Qu Q, Yang X, et al. Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus. BMC Microbiol. 2022;22(1):105.PubMedPubMedCentralCrossRef
6.
go back to reference Kleiner, David E, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2015;20(2):293–312. Kleiner, David E, Makhlouf HR. Histology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2015;20(2):293–312.
7.
go back to reference Gawrieh S, Chalasani N. Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2017;22(1):189–99.PubMedCrossRef Gawrieh S, Chalasani N. Emerging treatments for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clin Liver Dis. 2017;22(1):189–99.PubMedCrossRef
8.
go back to reference Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology. 2015;149(6):1305–8.PubMedCrossRef Kleiner DE, Bedossa P. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists. Gastroenterology. 2015;149(6):1305–8.PubMedCrossRef
9.
go back to reference Tilg H, Moschen AR. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol. 2011;55(5):960–2.PubMedCrossRef Tilg H, Moschen AR. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol. 2011;55(5):960–2.PubMedCrossRef
10.
go back to reference Bhowmick S, Singh V, Jash S, Lal M, Sinha RS. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion. 2021;58:24–37.PubMedCrossRef Bhowmick S, Singh V, Jash S, Lal M, Sinha RS. Mitochondrial metabolism and calcium homeostasis in the development of NAFLD leading to hepatocellular carcinoma. Mitochondrion. 2021;58:24–37.PubMedCrossRef
11.
go back to reference Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabolism Open. 2021;12: 100149.PubMedPubMedCentralCrossRef Zarghamravanbakhsh P, Frenkel M, Poretsky L. Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD). Metabolism Open. 2021;12: 100149.PubMedPubMedCentralCrossRef
12.
go back to reference Gong F, Zheng KI, Tang L, Li G, Rios RS, Huang O, et al. Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor? iLiver. 2022;1(1):30–34. Gong F, Zheng KI, Tang L, Li G, Rios RS, Huang O, et al. Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor? iLiver. 2022;1(1):30–34.
13.
go back to reference Zambrano-Huailla R, Guedes L, Stefano JT, Arrais DS, Arthur A, Marciano S, et al. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Ann Hepatol. 2020;19(6):622–6.PubMedCrossRef Zambrano-Huailla R, Guedes L, Stefano JT, Arrais DS, Arthur A, Marciano S, et al. Diagnostic performance of three non-invasive fibrosis scores (Hepamet, FIB-4, NAFLD fibrosis score) in NAFLD patients from a mixed Latin American population. Ann Hepatol. 2020;19(6):622–6.PubMedCrossRef
14.
go back to reference Xiong Y, Wen S, Li Y, Wei Y, Fang B, Li C, et al. Comprehensive analysis of transcriptomics and metabolomics to illustrate the underlying mechanism of helenalin against hepatic fibrosis. Eur J Pharmacol. 2022;919: 174770.PubMedCrossRef Xiong Y, Wen S, Li Y, Wei Y, Fang B, Li C, et al. Comprehensive analysis of transcriptomics and metabolomics to illustrate the underlying mechanism of helenalin against hepatic fibrosis. Eur J Pharmacol. 2022;919: 174770.PubMedCrossRef
15.
go back to reference Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks DF, Nordling A, Johansson I, et al. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis. Cells. 2020;9(4):964.PubMedPubMedCentralCrossRef Hurrell T, Kastrinou-Lampou V, Fardellas A, Hendriks DF, Nordling A, Johansson I, et al. Human liver spheroids as a model to study aetiology and treatment of hepatic fibrosis. Cells. 2020;9(4):964.PubMedPubMedCentralCrossRef
16.
go back to reference •• Gao L, Ma J, Fan Y, Zhang Y, Ge R, Tao X, et al. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol. 2021;183:1379–92. Research has revealed that goji berry polysaccharides can be considered as a prebiotic formulation, and LBP+AE may be a promising method for treating NAFLD, as it can maintain the balance of intestinal microbiota, thereby restoring the intestinal barrier and benefiting the liver. •• Gao L, Ma J, Fan Y, Zhang Y, Ge R, Tao X, et al. Lycium barbarum polysaccharide combined with aerobic exercise ameliorated nonalcoholic fatty liver disease through restoring gut microbiota, intestinal barrier and inhibiting hepatic inflammation. Int J Biol Macromol. 2021;183:1379–92. Research has revealed that goji berry polysaccharides can be considered as a prebiotic formulation, and LBP+AE may be a promising method for treating NAFLD, as it can maintain the balance of intestinal microbiota, thereby restoring the intestinal barrier and benefiting the liver.
17.
go back to reference Zou C, Fang Y, Lin N, Liu H. Polysaccharide extract from pomelo fruitlet ameliorates diet-induced nonalcoholic fatty liver disease in hybrid grouper (Epinephelus lanceolatus x Epinephelus fuscoguttatus). Fish Shellfish Immunol. 2021;119:114–27.PubMedCrossRef Zou C, Fang Y, Lin N, Liu H. Polysaccharide extract from pomelo fruitlet ameliorates diet-induced nonalcoholic fatty liver disease in hybrid grouper (Epinephelus lanceolatus x Epinephelus fuscoguttatus). Fish Shellfish Immunol. 2021;119:114–27.PubMedCrossRef
18.
go back to reference Wang P, Zhang X, Luo P, Jiang X, Zhang P, Guo J, et al. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nat Commun. 2016;7:10592.PubMedPubMedCentralCrossRefADS Wang P, Zhang X, Luo P, Jiang X, Zhang P, Guo J, et al. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nat Commun. 2016;7:10592.PubMedPubMedCentralCrossRefADS
19.
go back to reference Sun W, Li X, Dou H, Wang X, Li J, Shen L, et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. 2021;36(9): 109641.PubMedCrossRef Sun W, Li X, Dou H, Wang X, Li J, Shen L, et al. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep. 2021;36(9): 109641.PubMedCrossRef
20.
go back to reference Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology. Br J Clin Pharmacol. 2012;75(3):645–62.CrossRef Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology. Br J Clin Pharmacol. 2012;75(3):645–62.CrossRef
21.
go back to reference Kaliannan K, Li XY, Wang B, Pan Q, Chen C, Hao L, et al. Multi-omic analysis in transgenic mice implicates omega-6/omega-3 fatty acid imbalance as a risk factor for chronic disease. Commun Biol. 2019;2(1):1–18.CrossRef Kaliannan K, Li XY, Wang B, Pan Q, Chen C, Hao L, et al. Multi-omic analysis in transgenic mice implicates omega-6/omega-3 fatty acid imbalance as a risk factor for chronic disease. Commun Biol. 2019;2(1):1–18.CrossRef
22.
go back to reference Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr. 2010;30(1):6–19.PubMedCrossRef Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr. 2010;30(1):6–19.PubMedCrossRef
23.
go back to reference Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. BMC Nutr. 2021;7(1):86.PubMedPubMedCentralCrossRef Sangouni AA, Orang Z, Mozaffari-Khosravi H. Effect of omega-3 supplementation on cardiometabolic indices in diabetic patients with non-alcoholic fatty liver disease: a randomized controlled trial. BMC Nutr. 2021;7(1):86.PubMedPubMedCentralCrossRef
24.
go back to reference •• Batista ES, Da SR, Munoz VR, Jesus JS, Vasconcelos MM, Da CD, et al. Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the “Brazilian Omega Study” (BROS)-a randomized controlled trial. Trials. 2021;22(1):927. This study shows that inflammation and weakened ER stress signaling pathways in overweight and NAFLD participants will be supplemented by binding to the GPR120 receptor ω 3 to achieve. •• Batista ES, Da SR, Munoz VR, Jesus JS, Vasconcelos MM, Da CD, et al. Omega-3 mechanism of action in inflammation and endoplasmic reticulum stress in mononuclear cells from overweight non-alcoholic fatty liver disease participants: study protocol for the “Brazilian Omega Study” (BROS)-a randomized controlled trial. Trials. 2021;22(1):927. This study shows that inflammation and weakened ER stress signaling pathways in overweight and NAFLD participants will be supplemented by binding to the GPR120 receptor ω 3 to achieve.
25.
go back to reference Yan J, Guan B, Gao H, Peng X. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Medicine. 2018;97: e12271.PubMedPubMedCentralCrossRef Yan J, Guan B, Gao H, Peng X. Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Medicine. 2018;97: e12271.PubMedPubMedCentralCrossRef
26.
go back to reference Elhessy HM, Eltahry H, Erfan OS, Mahdi MR, Hazem NM, El-Shahat MA. Evaluation of the modulation of nitric oxide synthase expression in the cerebellum of diabetic albino rats and the possible protective effect of ferulic acid. Acta Histochem. 2020;122(8): 151633.PubMedCrossRef Elhessy HM, Eltahry H, Erfan OS, Mahdi MR, Hazem NM, El-Shahat MA. Evaluation of the modulation of nitric oxide synthase expression in the cerebellum of diabetic albino rats and the possible protective effect of ferulic acid. Acta Histochem. 2020;122(8): 151633.PubMedCrossRef
27.
go back to reference Yuan J, Ge K, Mu J, Rong J, Zhang L, Wang B, et al. Ferulic acid attenuated acetaminophen-induced hepatotoxicity though down-regulating the cytochrome P 2E1 and inhibiting toll-like receptor 4 signaling-mediated inflammation in mice. Am J Transl Res. 2016;8(10):4205–14.PubMedPubMedCentral Yuan J, Ge K, Mu J, Rong J, Zhang L, Wang B, et al. Ferulic acid attenuated acetaminophen-induced hepatotoxicity though down-regulating the cytochrome P 2E1 and inhibiting toll-like receptor 4 signaling-mediated inflammation in mice. Am J Transl Res. 2016;8(10):4205–14.PubMedPubMedCentral
28.
go back to reference Luo Z, Li M, Yang Q, Zhang Y, Liu F, Gong L, et al. Ferulic acid prevents nonalcoholic fatty liver disease by promoting fatty acid oxidation and energy expenditure in C57BL/6 mice fed a high-fat diet. Nutrients. 2022;14(12):2530.PubMedPubMedCentralCrossRef Luo Z, Li M, Yang Q, Zhang Y, Liu F, Gong L, et al. Ferulic acid prevents nonalcoholic fatty liver disease by promoting fatty acid oxidation and energy expenditure in C57BL/6 mice fed a high-fat diet. Nutrients. 2022;14(12):2530.PubMedPubMedCentralCrossRef
29.
go back to reference Shi X, Zhou X, Chu X, Wang J, Xie B, Ge J, et al. Allicin improves metabolism in high-fat diet-induced obese mice by modulating the gut microbiota. Nutrients. 2019;11(12):2019.CrossRef Shi X, Zhou X, Chu X, Wang J, Xie B, Ge J, et al. Allicin improves metabolism in high-fat diet-induced obese mice by modulating the gut microbiota. Nutrients. 2019;11(12):2019.CrossRef
30.
go back to reference Tirkey N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol. 2005;5. Tirkey N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol. 2005;5.
31.
go back to reference Chen H, Nie T, Zhang P, Ma J, Shan. Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. Life Sci. 2022;296:120428. Chen H, Nie T, Zhang P, Ma J, Shan. Hesperidin attenuates hepatic lipid accumulation in mice fed high-fat diet and oleic acid induced HepG2 via AMPK activation. Life Sci. 2022;296:120428.
32.
go back to reference Kong R, Wang N, Luo H, Lu J. Hesperetin mitigates bile duct ligation-induced liver fibrosis by inhibiting extracellular matrix and cell apoptosis via the TGF-β1/Smad pathway. Curr Mol Med. 2018;18(1):15–24.PubMedCrossRef Kong R, Wang N, Luo H, Lu J. Hesperetin mitigates bile duct ligation-induced liver fibrosis by inhibiting extracellular matrix and cell apoptosis via the TGF-β1/Smad pathway. Curr Mol Med. 2018;18(1):15–24.PubMedCrossRef
33.
go back to reference El-Sisi AEE, Sokar SS, Shebl AM, Mohamed DZ. Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. Biomed Pharmacother. 2017;89:1196–206.PubMedCrossRef El-Sisi AEE, Sokar SS, Shebl AM, Mohamed DZ. Antifibrotic effect of diethylcarbamazine combined with hesperidin against ethanol induced liver fibrosis in rats. Biomed Pharmacother. 2017;89:1196–206.PubMedCrossRef
34.
go back to reference Morsy MA, Nair AB. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers. Int J Pharm. 2018;552:241–50.PubMedCrossRef Morsy MA, Nair AB. Prevention of rat liver fibrosis by selective targeting of hepatic stellate cells using hesperidin carriers. Int J Pharm. 2018;552:241–50.PubMedCrossRef
35.
go back to reference Nasehi Z, Kheiripour N, Taheri MA, Ardjmand A, Jozi F, Shahaboddin ME. Efficiency of hesperidin against liver fibrosis induced by bile duct ligation in rats. Biomed Res Int. 2023;2023:5444301.PubMedPubMedCentralCrossRef Nasehi Z, Kheiripour N, Taheri MA, Ardjmand A, Jozi F, Shahaboddin ME. Efficiency of hesperidin against liver fibrosis induced by bile duct ligation in rats. Biomed Res Int. 2023;2023:5444301.PubMedPubMedCentralCrossRef
36.
go back to reference Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96(9):2711–7.PubMedCrossRef Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol. 2001;96(9):2711–7.PubMedCrossRef
37.
go back to reference Bingul I, Basaran-Kucukgergin C, Aydin AF, Coban J, Dogan-Ekici I, Dogru-Abbasoglu S, et al. Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis. Environ Toxicol Pharmacol. 2016;45:170–8.PubMedCrossRef Bingul I, Basaran-Kucukgergin C, Aydin AF, Coban J, Dogan-Ekici I, Dogru-Abbasoglu S, et al. Betaine treatment decreased oxidative stress, inflammation, and stellate cell activation in rats with alcoholic liver fibrosis. Environ Toxicol Pharmacol. 2016;45:170–8.PubMedCrossRef
38.
go back to reference Mo C, Xie S, Zeng T, Lai Y, Huang S, Zhou C, et al. Ginsenoside-Rg1 acts as an IDO1 inhibitor, protects against liver fibrosis via alleviating IDO1-mediated the inhibition of DCs maturation. Phytomedicine. 2021;84: 153524.PubMedCrossRef Mo C, Xie S, Zeng T, Lai Y, Huang S, Zhou C, et al. Ginsenoside-Rg1 acts as an IDO1 inhibitor, protects against liver fibrosis via alleviating IDO1-mediated the inhibition of DCs maturation. Phytomedicine. 2021;84: 153524.PubMedCrossRef
39.
go back to reference Yuan S, Dong M, Zhang H, Jiang X, Yan C, Ye R, et al. Ginsenoside PPD inhibit the activation of HSCs by directly targeting TGFβR1. Int J Biol Macromol. 2022;194:556–62.PubMedCrossRef Yuan S, Dong M, Zhang H, Jiang X, Yan C, Ye R, et al. Ginsenoside PPD inhibit the activation of HSCs by directly targeting TGFβR1. Int J Biol Macromol. 2022;194:556–62.PubMedCrossRef
40.
go back to reference Qu L, Zhu Y, Liu Y, Yang H, Zhu C, Ma P. Protective effects of ginsenoside Rk3 against chronic alcohol-induced liver injury in mice through inhibition of inflammation, oxidative stress, and apoptosis. Food Chem Toxicol. 2019;126:277–84.PubMedCrossRef Qu L, Zhu Y, Liu Y, Yang H, Zhu C, Ma P. Protective effects of ginsenoside Rk3 against chronic alcohol-induced liver injury in mice through inhibition of inflammation, oxidative stress, and apoptosis. Food Chem Toxicol. 2019;126:277–84.PubMedCrossRef
41.
go back to reference Liu X, Mi X, Wang Z, Zhang M, Hou J, Jiang S, et al. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis. 2020;11(6):454.PubMedPubMedCentralCrossRef Liu X, Mi X, Wang Z, Zhang M, Hou J, Jiang S, et al. Ginsenoside Rg3 promotes regression from hepatic fibrosis through reducing inflammation-mediated autophagy signaling pathway. Cell Death Dis. 2020;11(6):454.PubMedPubMedCentralCrossRef
42.
go back to reference • He Z, Chen S, Pan T, Li A, Wang K, Lin Z, et al. Ginsenoside Rg2 ameliorating CDAHFD-induced hepatic fibrosis by Regulating AKT/mTOR-mediated autophagy. J Agric Food Chem. 2022;70(6):1911–22. This study evaluates the potential anti fibrotic effects of G-Rg2, including possible mechanisms. For the first time, it has been revealed whether G-Rg2 can inhibit HSC autophagy without affecting or promoting liver cell autophagy, thereby more safely and effectively inhibiting liver fibrosis. • He Z, Chen S, Pan T, Li A, Wang K, Lin Z, et al. Ginsenoside Rg2 ameliorating CDAHFD-induced hepatic fibrosis by Regulating AKT/mTOR-mediated autophagy. J Agric Food Chem. 2022;70(6):1911–22. This study evaluates the potential anti fibrotic effects of G-Rg2, including possible mechanisms. For the first time, it has been revealed whether G-Rg2 can inhibit HSC autophagy without affecting or promoting liver cell autophagy, thereby more safely and effectively inhibiting liver fibrosis.
43.
go back to reference Wei X, Chen Y, Huang W. Ginsenoside Rg1 ameliorates liver fibrosis via suppressing epithelial to mesenchymal transition and reactive oxygen species production in vitro and in vivo. BioFactors. 2018;44(4):327–35.CrossRef Wei X, Chen Y, Huang W. Ginsenoside Rg1 ameliorates liver fibrosis via suppressing epithelial to mesenchymal transition and reactive oxygen species production in vitro and in vivo. BioFactors. 2018;44(4):327–35.CrossRef
44.
go back to reference Cai Y, Li H, Liu M, Pei Y, Zheng J, Zhou J, et al. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology. 2018;68(1):48–61.PubMedCrossRef Cai Y, Li H, Liu M, Pei Y, Zheng J, Zhou J, et al. Disruption of adenosine 2A receptor exacerbates NAFLD through increasing inflammatory responses and SREBP1c activity. Hepatology. 2018;68(1):48–61.PubMedCrossRef
45.
go back to reference Wei X, Chen Y, Huang W. Ginsenoside Rg1 ameliorates liver fibrosis via suppressing epithelial to mesenchymal transition and reactive oxygen species production in vitro and in vivo. Biofactors. 2018;44(4). Wei X, Chen Y, Huang W. Ginsenoside Rg1 ameliorates liver fibrosis via suppressing epithelial to mesenchymal transition and reactive oxygen species production in vitro and in vivo. Biofactors. 2018;44(4).
46.
go back to reference Li Y, Zhang D, Li L, Han Y, Dong X, Yang L, et al. Ginsenoside Rg1 ameliorates aging‑induced liver fibrosis by inhibiting the NOX4/NLRP3 inflammasome in SAMP8 mice. Mol Med Rep. 2021;24. Li Y, Zhang D, Li L, Han Y, Dong X, Yang L, et al. Ginsenoside Rg1 ameliorates aging‑induced liver fibrosis by inhibiting the NOX4/NLRP3 inflammasome in SAMP8 mice. Mol Med Rep. 2021;24.
47.
go back to reference Zhang R, Li X, Gao Y, Tao Q, Lang Z, Zhan Y, et al. Ginsenoside Rg1 epigenetically modulates Smad7 expression in liver fibrosis via MicroRNA-152. J Ginseng Res. 2023;47:534–42.PubMedCrossRef Zhang R, Li X, Gao Y, Tao Q, Lang Z, Zhan Y, et al. Ginsenoside Rg1 epigenetically modulates Smad7 expression in liver fibrosis via MicroRNA-152. J Ginseng Res. 2023;47:534–42.PubMedCrossRef
48.
go back to reference • Zaghloul RA, Zaghloul AM, El-Kashef DH. Hepatoprotective effect of Baicalin against thioacetamide-induced cirrhosis in rats: targeting NOX4/NF-κB/NLRP3 inflammasome signaling pathways. Life Sci. 2022;295:120410. This study conducted an in-depth study on the liver protective effect of the edible ingredient Baicalin, which is administered through TGF-β 1/NOX4/NF-κ. The B/NLRP3 pathway exerts anti-fibrotic effects while also exhibiting anti-inflammatory and antioxidant effects. Baicalin targets NOX4/NF-κ. The B/NLRP3 inflammasome pathway has been evaluated as a possible mechanism of its potential anti-fibrotic effect. • Zaghloul RA, Zaghloul AM, El-Kashef DH. Hepatoprotective effect of Baicalin against thioacetamide-induced cirrhosis in rats: targeting NOX4/NF-κB/NLRP3 inflammasome signaling pathways. Life Sci. 2022;295:120410. This study conducted an in-depth study on the liver protective effect of the edible ingredient Baicalin, which is administered through TGF-β 1/NOX4/NF-κ. The B/NLRP3 pathway exerts anti-fibrotic effects while also exhibiting anti-inflammatory and antioxidant effects. Baicalin targets NOX4/NF-κ. The B/NLRP3 inflammasome pathway has been evaluated as a possible mechanism of its potential anti-fibrotic effect.
49.
go back to reference Xiao Y, Ye J, Zhou Y, Huang J, Liu X, Huang B, et al. Baicalin inhibits pressure overload-induced cardiac fibrosis through regulating AMPK/TGF-β/Smads signaling pathway. Arch Biochem Biophys. 2018;640:37–46.PubMedCrossRef Xiao Y, Ye J, Zhou Y, Huang J, Liu X, Huang B, et al. Baicalin inhibits pressure overload-induced cardiac fibrosis through regulating AMPK/TGF-β/Smads signaling pathway. Arch Biochem Biophys. 2018;640:37–46.PubMedCrossRef
50.
go back to reference Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, et al. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Arch Biochem Biophys. 2020;80: 106208. Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, et al. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Arch Biochem Biophys. 2020;80: 106208.
51.
go back to reference Zhang J, Zhang H, Deng X, Zhang N, Liu B, Xin S, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 2017;192:46–54.PubMedCrossRefADS Zhang J, Zhang H, Deng X, Zhang N, Liu B, Xin S, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism, inflammation and fibrosis in mice. Life Sci. 2017;192:46–54.PubMedCrossRefADS
52.
go back to reference Shen K, Feng X, Pan H, Zhang F, Xie H, Zheng S. Baicalin ameliorates experimental liver cholestasis in mice by modulation of oxidative stress, inflammation, and NRF2 transcription factor. Oxid Med Cell Longev. 2017;6169128:1–11. Shen K, Feng X, Pan H, Zhang F, Xie H, Zheng S. Baicalin ameliorates experimental liver cholestasis in mice by modulation of oxidative stress, inflammation, and NRF2 transcription factor. Oxid Med Cell Longev. 2017;6169128:1–11.
53.
go back to reference El-Hameed NM, El-Aleem SA, Khattab MA, Ali AH, Mohammed HH. Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). Life Sci. 2021;285: 119983.CrossRef El-Hameed NM, El-Aleem SA, Khattab MA, Ali AH, Mohammed HH. Curcumin activation of nuclear factor E2-related factor 2 gene (Nrf2): prophylactic and therapeutic effect in nonalcoholic steatohepatitis (NASH). Life Sci. 2021;285: 119983.CrossRef
54.
go back to reference Che Y, Shi X, Zhong X, Zhang Y, Si R, Li Y, et al. Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. J Nutr Biochem. 2020;82: 108400.PubMedCrossRef Che Y, Shi X, Zhong X, Zhang Y, Si R, Li Y, et al. Resveratrol prevents liver damage in MCD-induced steatohepatitis mice by promoting SIGIRR gene transcription. J Nutr Biochem. 2020;82: 108400.PubMedCrossRef
55.
go back to reference Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014;63:166–73.PubMedCrossRef Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014;63:166–73.PubMedCrossRef
56.
go back to reference Abd-Elgawad H, Abu-Elsaad N, El-Karef A, Ibrahim T. Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Can J Physiol Pharmacol. 2016;94(7):779–87.PubMedCrossRef Abd-Elgawad H, Abu-Elsaad N, El-Karef A, Ibrahim T. Piceatannol increases the expression of hepatocyte growth factor and IL-10 thereby protecting hepatocytes in thioacetamide-induced liver fibrosis. Can J Physiol Pharmacol. 2016;94(7):779–87.PubMedCrossRef
57.
go back to reference Liang F, Xu X, Tu Y. Resveratrol inhibited hepatocyte apoptosis and alleviated liver fibrosis through miR-190a-5p /HGF axis. Bioorg Med Chem. 2022;57: 116593.PubMedCrossRef Liang F, Xu X, Tu Y. Resveratrol inhibited hepatocyte apoptosis and alleviated liver fibrosis through miR-190a-5p /HGF axis. Bioorg Med Chem. 2022;57: 116593.PubMedCrossRef
58.
go back to reference Albrahim T, Alonazi MA. Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, antifibrotic pathways. Biomed Pharmacother. 2021;141: 111831.PubMedCrossRef Albrahim T, Alonazi MA. Lycopene corrects metabolic syndrome and liver injury induced by high fat diet in obese rats through antioxidant, anti-inflammatory, antifibrotic pathways. Biomed Pharmacother. 2021;141: 111831.PubMedCrossRef
59.
go back to reference Saeed NM, Mansour AM, Allam S. Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. Pharma Nutrition. 2020;14(1): 100225.CrossRef Saeed NM, Mansour AM, Allam S. Lycopene induces insulin signaling and alleviates fibrosis in experimental model of non-alcoholic fatty liver disease in rats. Pharma Nutrition. 2020;14(1): 100225.CrossRef
60.
go back to reference Zeng Z, He W, Jia Z, Hao S. Lycopene improves insulin sensitivity through inhibition of STAT3/Srebp-1c-mediated lipid accumulation and inflammation in mice fed a high-fat diet. Exp Clin Endocrinol Diabetes. 2017;125:610–7.PubMedCrossRef Zeng Z, He W, Jia Z, Hao S. Lycopene improves insulin sensitivity through inhibition of STAT3/Srebp-1c-mediated lipid accumulation and inflammation in mice fed a high-fat diet. Exp Clin Endocrinol Diabetes. 2017;125:610–7.PubMedCrossRef
61.
go back to reference Liu P, Wu P, Yang B, Wang T, Li J, Song X, et al. Kaempferol prevents the progression from simple steatosis to non-alcoholic steatohepatitis by inhibiting the NF-κB pathway in oleic acid-induced HepG2 cells and high-fat diet-induced rats. J Funct Foods. 2021;85: 104655.CrossRef Liu P, Wu P, Yang B, Wang T, Li J, Song X, et al. Kaempferol prevents the progression from simple steatosis to non-alcoholic steatohepatitis by inhibiting the NF-κB pathway in oleic acid-induced HepG2 cells and high-fat diet-induced rats. J Funct Foods. 2021;85: 104655.CrossRef
62.
go back to reference Lu Y, Shao M, Xiang H, Zheng P, Wu T, Ji G. Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis. Food Function. 2020;11:10058–9.PubMedCrossRef Lu Y, Shao M, Xiang H, Zheng P, Wu T, Ji G. Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis. Food Function. 2020;11:10058–9.PubMedCrossRef
63.
go back to reference Lemmens KJA, Van De Wier B, Koek GH, Köhler E, Drittij MJ, Van Der Vijgh WJF, et al. Haenen GRMM: the flavonoid monoHER promotes the adaption to oxidative stress during the onset of NAFLD. Biochem Biophys Res Commun. 2015;456:179–82.PubMedCrossRef Lemmens KJA, Van De Wier B, Koek GH, Köhler E, Drittij MJ, Van Der Vijgh WJF, et al. Haenen GRMM: the flavonoid monoHER promotes the adaption to oxidative stress during the onset of NAFLD. Biochem Biophys Res Commun. 2015;456:179–82.PubMedCrossRef
64.
go back to reference Miao Y, Wu Y, Jin Y, Lei M, Nan J, Wu X. Benzoquinone derivatives with antioxidant activity inhibit activated hepatic stellate cells and attenuate liver fibrosis in TAA-induced mice. Chem-Biol Interact. 2020;317: 108945.PubMedCrossRef Miao Y, Wu Y, Jin Y, Lei M, Nan J, Wu X. Benzoquinone derivatives with antioxidant activity inhibit activated hepatic stellate cells and attenuate liver fibrosis in TAA-induced mice. Chem-Biol Interact. 2020;317: 108945.PubMedCrossRef
65.
go back to reference Zhong X, Liu H. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways. Biomed Pharmacother. 2018;98:111–7.PubMedCrossRef Zhong X, Liu H. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways. Biomed Pharmacother. 2018;98:111–7.PubMedCrossRef
66.
go back to reference Wang F, Liu JC, Zhou RJ, Zhao X, Liu M, Ye H, et al. Apigenin protects against alcohol-induced liver injury in mice by regulating hepatic CYP2E1-mediated oxidative stress and PPARalpha-mediated lipogenic gene expression. Chem Biol Interact. 2017;275:171–7.PubMedCrossRef Wang F, Liu JC, Zhou RJ, Zhao X, Liu M, Ye H, et al. Apigenin protects against alcohol-induced liver injury in mice by regulating hepatic CYP2E1-mediated oxidative stress and PPARalpha-mediated lipogenic gene expression. Chem Biol Interact. 2017;275:171–7.PubMedCrossRef
67.
go back to reference Tsai MS, Wang YH, Lai YY, Tsou HK, Liou GG, Ko JL, et al. Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice. Toxicol Lett. 2018;290:97–109.PubMedCrossRef Tsai MS, Wang YH, Lai YY, Tsou HK, Liou GG, Ko JL, et al. Kaempferol protects against propacetamol-induced acute liver injury through CYP2E1 inactivation, UGT1A1 activation, and attenuation of oxidative stress, inflammation and apoptosis in mice. Toxicol Lett. 2018;290:97–109.PubMedCrossRef
68.
go back to reference Shi M, Cui Y, Liu C, Li C, Liu Z, Kang WY. CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes. Food Chem Toxicol. 2020;136: 111027.PubMedCrossRef Shi M, Cui Y, Liu C, Li C, Liu Z, Kang WY. CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes. Food Chem Toxicol. 2020;136: 111027.PubMedCrossRef
69.
go back to reference Pingili RB, Pawar AK, Challa SR. Effect of chrysin on the formation of N-acetyl-p-benzoquinoneimine, a toxic metabolite of paracetamol in rats and isolated rat hepatocytes. Chem Biol Interact. 2019;302:123–34.PubMedCrossRef Pingili RB, Pawar AK, Challa SR. Effect of chrysin on the formation of N-acetyl-p-benzoquinoneimine, a toxic metabolite of paracetamol in rats and isolated rat hepatocytes. Chem Biol Interact. 2019;302:123–34.PubMedCrossRef
70.
go back to reference Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019;9:745–57.PubMedPubMedCentralCrossRef Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B. 2019;9:745–57.PubMedPubMedCentralCrossRef
71.
72.
go back to reference He P, Wu Y, Shun J, Liang Y, Cheng M, Wang Y. Baicalin ameliorates liver injury induced by chronic plus binge ethanol feeding by modulating oxidative stress and inflammation via CYP2E1 and NRF2 in mice. Oxid Med Cell Longev. 2017;2017:4820414.PubMedPubMedCentralCrossRef He P, Wu Y, Shun J, Liang Y, Cheng M, Wang Y. Baicalin ameliorates liver injury induced by chronic plus binge ethanol feeding by modulating oxidative stress and inflammation via CYP2E1 and NRF2 in mice. Oxid Med Cell Longev. 2017;2017:4820414.PubMedPubMedCentralCrossRef
73.
go back to reference Caro AA, Davis A, Fobare S, Horan N, Ryan C, Schwab C. Antioxidant and pro-oxidant mechanisms of (+) catechin in microsomal CYP2E1-dependent oxidative stress. Toxicol In Vitro. 2019;54:1–9.PubMedCrossRef Caro AA, Davis A, Fobare S, Horan N, Ryan C, Schwab C. Antioxidant and pro-oxidant mechanisms of (+) catechin in microsomal CYP2E1-dependent oxidative stress. Toxicol In Vitro. 2019;54:1–9.PubMedCrossRef
74.
go back to reference Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta Gen Subj. 1999;1472:643–50.CrossRef Gao Z, Huang K, Yang X, Xu H. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta Gen Subj. 1999;1472:643–50.CrossRef
75.
go back to reference Liao X, Wen Q, Zhang L, Lu L, Zhang L, Luo X. Effect of dietary supplementation with flavonoid from Scutellaria baicalensis Georgi on growth performance, meat quality and antioxidative ability of broilers. J Integr Agr. 2018;17:1165–70.CrossRef Liao X, Wen Q, Zhang L, Lu L, Zhang L, Luo X. Effect of dietary supplementation with flavonoid from Scutellaria baicalensis Georgi on growth performance, meat quality and antioxidative ability of broilers. J Integr Agr. 2018;17:1165–70.CrossRef
76.
go back to reference Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, et al. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res. 2021;405: 112689.PubMedCrossRef Yu H, Jiang X, Dong F, Zhang F, Ji X, Xue M, et al. Lipid accumulation-induced hepatocyte senescence regulates the activation of hepatic stellate cells through the Nrf2-antioxidant response element pathway. Exp Cell Res. 2021;405: 112689.PubMedCrossRef
77.
go back to reference Zhao H, Eguchi S, Alam A, Ma D. The role of nuclear factor-erythroid 2 related factor 2 (Nrf-2) in the protection against lung injury. Am J Physiol Lung Cell Mol Physiol. 2017;312:155–62.CrossRef Zhao H, Eguchi S, Alam A, Ma D. The role of nuclear factor-erythroid 2 related factor 2 (Nrf-2) in the protection against lung injury. Am J Physiol Lung Cell Mol Physiol. 2017;312:155–62.CrossRef
78.
go back to reference Lu X, Liu M, Dong H, Miao J, Stagos D, Liu M. Dietary prenylated flavonoid xanthohumol alleviates oxidative damage and accelerates diabetic wound healing via Nrf2 activation. Food Chem Toxicol. 2022;160: 112813.PubMedCrossRef Lu X, Liu M, Dong H, Miao J, Stagos D, Liu M. Dietary prenylated flavonoid xanthohumol alleviates oxidative damage and accelerates diabetic wound healing via Nrf2 activation. Food Chem Toxicol. 2022;160: 112813.PubMedCrossRef
79.
go back to reference Kabirifar R, Ghoreshi Z, Rezaifar A, Binesh F, Bamdad K, Moradi A. Curcumin, quercetin and atorvastatin protected against the hepatic fibrosis by activating AMP-activated protein kinase. J Funct Foods. 2018;40:341–8.CrossRef Kabirifar R, Ghoreshi Z, Rezaifar A, Binesh F, Bamdad K, Moradi A. Curcumin, quercetin and atorvastatin protected against the hepatic fibrosis by activating AMP-activated protein kinase. J Funct Foods. 2018;40:341–8.CrossRef
80.
go back to reference Zhu X, Lin X, Zhang P, Liu Y, Ling W, Guo H. Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: a case-control and an intervention study. Clin Gastroenterol Hepatol. 2022;46: 101843.CrossRef Zhu X, Lin X, Zhang P, Liu Y, Ling W, Guo H. Upregulated NLRP3 inflammasome activation is attenuated by anthocyanins in patients with nonalcoholic fatty liver disease: a case-control and an intervention study. Clin Gastroenterol Hepatol. 2022;46: 101843.CrossRef
81.
go back to reference Zhu X, Xiong T, Liu P, Guo X, Xiao L, Zhou F, et al. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem Toxicol. 2018;114:52–60.PubMedCrossRef Zhu X, Xiong T, Liu P, Guo X, Xiao L, Zhou F, et al. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem Toxicol. 2018;114:52–60.PubMedCrossRef
82.
go back to reference Ge C, Yu R, Xu M, Li P, Fan C, Li J, et al. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Eur J Pharmacol. 2016;770:154–64.PubMedCrossRef Ge C, Yu R, Xu M, Li P, Fan C, Li J, et al. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats. Eur J Pharmacol. 2016;770:154–64.PubMedCrossRef
83.
go back to reference Hernández-Aquino E, Quezada-Ramírez MA, Silva-Olivares A, Ramos-Tovar E, Flores-Beltrán RE, Segovia J, et al. Curcumin downregulates Smad pathways and reduces hepatic stellate cells activation in experimental fibrosis. Ann Hepatol. 2020;19(5):497–506.PubMedCrossRef Hernández-Aquino E, Quezada-Ramírez MA, Silva-Olivares A, Ramos-Tovar E, Flores-Beltrán RE, Segovia J, et al. Curcumin downregulates Smad pathways and reduces hepatic stellate cells activation in experimental fibrosis. Ann Hepatol. 2020;19(5):497–506.PubMedCrossRef
84.
go back to reference Yu B, Qin S, Hu B, Qin Q, Jiang H, Luo W. Resveratrol improves CCL4-induced liver fibrosis in mouse by upregulating endogenous IL-10 to reprogramme macrophages phenotype from M(LPS) to M(IL-4). Biomed Pharmacother. 2019;117: 109110.PubMedCrossRef Yu B, Qin S, Hu B, Qin Q, Jiang H, Luo W. Resveratrol improves CCL4-induced liver fibrosis in mouse by upregulating endogenous IL-10 to reprogramme macrophages phenotype from M(LPS) to M(IL-4). Biomed Pharmacother. 2019;117: 109110.PubMedCrossRef
85.
go back to reference Zhou J, Zou Y, Cai Y, Chi F, Huang W, Shi W, et al. A designed cyclic peptide based on trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability. Bioorg Chem. 2021;117: 105453.PubMedCrossRef Zhou J, Zou Y, Cai Y, Chi F, Huang W, Shi W, et al. A designed cyclic peptide based on trastuzumab used to construct peptide-drug conjugates for its HER2-targeting ability. Bioorg Chem. 2021;117: 105453.PubMedCrossRef
86.
go back to reference Deng Z, Liu Y, Liu C, Xiang X, Wang J, Cheng Z, et al. Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology. 2009;50(2):1412–20.PubMedCrossRef Deng Z, Liu Y, Liu C, Xiang X, Wang J, Cheng Z, et al. Immature myeloid cells induced by a high-fat diet contribute to liver inflammation. Hepatology. 2009;50(2):1412–20.PubMedCrossRef
87.
go back to reference Peng CH, Lin HT, Chung DJ, Huang CN, Wang CJ. Mulberry leaf extracts prevent obesity-induced NAFLD with regulating adipocytokines, inflammation and oxidative stress. J Food Drug Anal. 2018;26(2):778–87.PubMedCrossRef Peng CH, Lin HT, Chung DJ, Huang CN, Wang CJ. Mulberry leaf extracts prevent obesity-induced NAFLD with regulating adipocytokines, inflammation and oxidative stress. J Food Drug Anal. 2018;26(2):778–87.PubMedCrossRef
88.
go back to reference Xiao J, Zhu Y, Liu Y, Tipoe GL, Xing F, So KF. Lycium barbarum polysaccharide attenuates alcoholic cellular injury through TXNIP-NLRP3 inflammasome pathway. Int J Biol Macromol. 2014;69:73–8.PubMedCrossRef Xiao J, Zhu Y, Liu Y, Tipoe GL, Xing F, So KF. Lycium barbarum polysaccharide attenuates alcoholic cellular injury through TXNIP-NLRP3 inflammasome pathway. Int J Biol Macromol. 2014;69:73–8.PubMedCrossRef
89.
go back to reference Dai L, Aye TC, Liu X, Xi J, Cheung PCF. TAK1, more than just innate immunity. IUBMB Life. 2012;64(10):825–34.PubMedCrossRef Dai L, Aye TC, Liu X, Xi J, Cheung PCF. TAK1, more than just innate immunity. IUBMB Life. 2012;64(10):825–34.PubMedCrossRef
90.
go back to reference Vazirian M, Nabavi SM, Jafari S, Manayi A. Natural activators of adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) and their pharmacological activities. Food Chem Toxicol. 2018;122:69–79.PubMedCrossRef Vazirian M, Nabavi SM, Jafari S, Manayi A. Natural activators of adenosine 5′-monophosphate (AMP)-activated protein kinase (AMPK) and their pharmacological activities. Food Chem Toxicol. 2018;122:69–79.PubMedCrossRef
91.
go back to reference Herrero-Martín G, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A, et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009;28(6):1532–632.PubMedCentralCrossRef Herrero-Martín G, Høyer-Hansen M, García-García C, Fumarola C, Farkas T, López-Rivas A, et al. TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated epithelial cells. EMBO J. 2009;28(6):1532–632.PubMedCentralCrossRef
92.
go back to reference Jiang W, Wang J, Xue W, Xin J, Shi C, Wen J, et al. Caveolin-1 attenuates acetaminophen aggravated lipid accumulation in alcoholic fatty liver by activating mitophagy via the Pink-1/Parkin pathway. Eur J Pharmacol. 2021;908: 174324.PubMedCrossRef Jiang W, Wang J, Xue W, Xin J, Shi C, Wen J, et al. Caveolin-1 attenuates acetaminophen aggravated lipid accumulation in alcoholic fatty liver by activating mitophagy via the Pink-1/Parkin pathway. Eur J Pharmacol. 2021;908: 174324.PubMedCrossRef
93.
go back to reference Kocot AM, Wróblewska B. Fermented products and bioactive food compounds as a tool to activate autophagy and promote the maintenance of the intestinal barrier function. Trends Food Sci Technol. 2021;118:905–19.CrossRef Kocot AM, Wróblewska B. Fermented products and bioactive food compounds as a tool to activate autophagy and promote the maintenance of the intestinal barrier function. Trends Food Sci Technol. 2021;118:905–19.CrossRef
94.
go back to reference Zheng X, Zhang X, Liu Y, Zhu L, Liang X, Jiang H, et al. Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. J Funct Foods. 2021;86: 104686.CrossRef Zheng X, Zhang X, Liu Y, Zhu L, Liang X, Jiang H, et al. Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. J Funct Foods. 2021;86: 104686.CrossRef
95.
go back to reference Yan L, Zhang S, Luo G, Cheng BC, Zhang C, Wang Y, et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. Metabolism. 2022;131: 155200.PubMedCrossRef Yan L, Zhang S, Luo G, Cheng BC, Zhang C, Wang Y, et al. Schisandrin B mitigates hepatic steatosis and promotes fatty acid oxidation by inducing autophagy through AMPK/mTOR signaling pathway. Metabolism. 2022;131: 155200.PubMedCrossRef
96.
go back to reference Dai C, Ciccotosto GD, Cappai R, Wang Y, Tang S, Hoyer D, et al. Rapamycin confers neuroprotection against colistin-induced oxidative stress, mitochondria dysfunction, and apoptosis through the activation of autophagy and mTOR/Akt/CREB signaling pathways. ACS Chem Neurosci. 2018;9(4):824–37.PubMedCrossRef Dai C, Ciccotosto GD, Cappai R, Wang Y, Tang S, Hoyer D, et al. Rapamycin confers neuroprotection against colistin-induced oxidative stress, mitochondria dysfunction, and apoptosis through the activation of autophagy and mTOR/Akt/CREB signaling pathways. ACS Chem Neurosci. 2018;9(4):824–37.PubMedCrossRef
97.
go back to reference Duan R, Huang K, Guan X, Li S, Xia J, Shen M, et al. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice. Food Chem Toxicol. 2022;164: 112948.PubMedCrossRef Duan R, Huang K, Guan X, Li S, Xia J, Shen M, et al. Tectorigenin ameliorated high-fat diet-induced nonalcoholic fatty liver disease through anti-inflammation and modulating gut microbiota in mice. Food Chem Toxicol. 2022;164: 112948.PubMedCrossRef
98.
go back to reference Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–85.PubMedPubMedCentralCrossRefADS Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179–85.PubMedPubMedCentralCrossRefADS
99.
go back to reference Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, et al. Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. J Funct Foods. 2015;15:464–75.PubMedPubMedCentralCrossRef Huang H, Chen AY, Rojanasakul Y, Ye X, Rankin GO, et al. Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. J Funct Foods. 2015;15:464–75.PubMedPubMedCentralCrossRef
100.
go back to reference Ajaz S, Mcphail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, et al. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion. 2021;57:119–30.PubMedCrossRef Ajaz S, Mcphail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, et al. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion. 2021;57:119–30.PubMedCrossRef
101.
go back to reference Lee J, Park JS, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res. 2019;42(11):935–46.PubMedCrossRef Lee J, Park JS, Roh YS. Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. Arch Pharm Res. 2019;42(11):935–46.PubMedCrossRef
102.
go back to reference Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, et al. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. J Funct Foods. 2021;82: 104496.CrossRef Ren F, Chen Q, Meng C, Chen H, Zhou Y, Zhang H, et al. Serum metabonomics revealed the mechanism of Ganoderma amboinense polysaccharides in preventing non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet. J Funct Foods. 2021;82: 104496.CrossRef
103.
go back to reference Ren T, Zhu L, Shen Y, Mou Q, Lin T, Feng H. Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease. Food Funct. 2019;10(3):1540–51.PubMedCrossRef Ren T, Zhu L, Shen Y, Mou Q, Lin T, Feng H. Protection of hepatocyte mitochondrial function by blueberry juice and probiotics via SIRT1 regulation in non-alcoholic fatty liver disease. Food Funct. 2019;10(3):1540–51.PubMedCrossRef
Metadata
Title
Functional Food Chemical Ingredient Strategies for Non-alcoholic Fatty Liver Disease (NAFLD) and Hepatic Fibrosis: Chemical Properties, Health Benefits, Action, and Application
Authors
Chong Yu
Xiaohe Guo
Xiaohang Cui
Guangyue Su
Haifeng Wang
Publication date
03-01-2024
Publisher
Springer US
Published in
Current Nutrition Reports / Issue 1/2024
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-023-00514-8

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more